Scoop: CellProthera eyes $30M round for PhIII trial of cell therapy for heart attacks: #Jefferies23
CellProthera plans to raise around $30 million in its first major fundraise to help advance its lead regenerative cell therapy program for patients who have recently experienced heart attacks into registrational development, Endpoints News has learned.
“We want to do the Phase III trial in both the US and EU, so we expect we need to raise as much as we’ve raised to date over several tranches, but this time in a single shot,” CEO Matthieu de Kalbermatten told Endpoints on Tuesday at the annual Jefferies healthcare conference in London.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.